We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

105 hedge funds and large institutions have $69.2M invested in Invesco Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 7

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

17% more capital invested

Capital invested by funds: $59M → $69.2M (+$10.2M)

13% more funds holding

Funds holding: 93105 (+12)

0.24% less ownership

Funds ownership: 22.23%21.99% (-0.24%)

Holders
105
Holders Change
+12
Holders Change %
+12.9%
% of All Funds
1.28%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
30
Reduced
17
Closed
7
Calls
Puts
Net Calls
Net Calls Change

PJP Hedge Fund Activity: Q4 2025 in Review

105 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2025, worth a combined $69.2M — up 17% from $59M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new PJP positions and 7 closed out — a net gain of 13 holders — while 30 added to existing stakes and 17 trimmed.

The largest buyer was Wells Fargo, adding an estimated $1.87M. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.15M sold.

  • 105 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2025, up from 93 in Q3 2025.
  • Funds reported $69.2M of Invesco Pharmaceuticals ETF stock for Q4 2025, up 17% quarter-over-quarter.
  • 20 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2025 and 7 closed out, a net change of +13 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q4 2025 was Wells Fargo, an estimated $1.87M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q4 2025 was Goldman Sachs, an estimated $2.15M sold.

Based on aggregated 13F filings for Q4 2025.